Overview

Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors

Status:
Completed
Trial end date:
2017-07-04
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of INC280 in patients with solid tumors that are refractory to current treatment or for which there is not a current standard of care and whose tumors have dysregulation of the c-MET pathway.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals